EUCTR2009-016800-22-IT进行中（未招募）不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) - BPAE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 575
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Male patients with a history of BPH and moderate-to-severe LUTS due to prostate enlargement, who are at least 45 years of age and who have given informed consent, are eligible to participate in this study. Eligible patients must: Have an IPSS >/=13 at the placebo lead-in visit (Visit 2). Have a TPV by TRUS >/=30 mL at Visit 2. Show signs of bladder outlet obstruction as defined by a peak urinary flow rate (Qmax) >/=4 and /=1.4 and 4 ng/mL, prostate cancer must be excluded via a documented prostate biopsy within 12 months of Visit 1 and prior to the patient s Visit 2. Demonstrate a Post Void Residual (PVR) /=300 ng/dL at screening (Visit 1). If hyperlipidemic, based on history, be on stable statin treatment as determined by the investigator for at least 2 months prior to Visit 2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from study participation if they: Have a history of BPH-related invasive procedures (for example, transurethral prostatectomy [TURP], open prostatectomy, and minimally invasive procedures that include thermal-based therapies, transurethral microwave treatment, transurethral needle ablation, and stents). Have active cardiovascular disease as evidenced by the following: oRecent myocardial infarction (MI), unstable angina, stroke, or transient ischemic attack (TIA) within 6 months of Visit 2. oRecent coronary intervention that includes coronary artery bypass surgery, percutaneous coronary artery intervention, or stent placement within 6 months of Visit 2. oRecent history of positive stress tests without any written documentation of effective intervention within 6 months of Visit 2. oEvidence of heart disease categorized as ≥Class III functional classification of New York Heart Association (NYHA) within 6 months of Visit 2. Have known or suspected history of prostate cancer, breast cancer, or other clinically significant neoplastic disease (other than squamous cell or basal cell carcinoma of skin). Have a history of deep venous thrombosis or pulmonary embolism disease. Have moderate to severe renal insufficiency (defined as an estimated glomerular filtration rate (eGFR) <50 mL/min/1.73m2 calculated from the Modification of Diet in Renal Disease [MDRD] formula [Huang et al. 2009]). Have a HbA1c >9.0%. Are on testosterone replacement therapy or on drugs that influence the hypothalamus-pituitary-gonadal axis, which may include any estrogen preparation, selective estrogen-receptor modulators (SERMs), gonadotropin releasing hormone (GnRH) agonists/antagonists, or androgen receptor antagonists within1 month prior to Visit 1. Patients on stable doses of thyroid replacement therapy will be allowed in this study. Are on pharmacological treatment other than statins for hyperlipidemia.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 12.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaBenign prostatic hyperplasiaEUCTR2009-016800-22-FREli Lilly and Company Limited575
进行中（未招募）
不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 12.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaBenign prostatic hyperplasiaEUCTR2009-016800-22-GREli Lilly and Company Limited575
进行中（未招募）
不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 13.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersBenign prostatic hyperplasiaEUCTR2009-016800-22-DEEli Lilly and Company Limited575
已完成
1 期
Phase 1 study of once-daily and alternate-day oral administration of S-1 in patients with locally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancerlocally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancerJPRN-UMIN000006195Wakayama Medical University9
进行中（未招募）
不适用
A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinomaPatients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinomaMedDRA version: 14.1Level: LLTClassification code 10014745Term: Endometrial carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024396-12-ITOVARTIS FARMA140